Isarna Therapeutics Announces First Patient Enrolled in Inte

Isarna Therapeutics today announced the enrollment of the first patient in the BETTER Study, a parallel, two-segment Phase 2a clinical study to evaluate Isarna's lead candidate ISTH0036 in patients

Related Keywords

Austria , India , Rupert Strauss , Kostenloser Wertpapierhandel , Marion Munk , Matthias Bolz , Desmond James , Claus Schalper , Kepler University In Linz , Trophic Communications , Lancet Glob Health , Isarna Therapeutics , Kepler University , Vascular Endothelial Growth Factors , Isarna , Herapeutics , Nnounces , First , Patient , Unrolled , Nternational , Hase , Linical , Study , Ophthalmology , Indications ,